Rebif

Roche MS candidate beats Rebif in latest PhIII as 2016 FDA decision awaits

Roche’s new multiple sclerosis drug has beaten out the aging MS treatment Rebif (interferon beta-1a) in a head-to-head late-stage test as it looks to a potential U.S. green light before the New Year.

Ben Adams Sep 14, 2016 6:41am